Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1151 - Phase 1 study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Clinical Research

Tumour Site

Presenters

Noboru Yamamoto

Citation

Annals of Oncology (2018) 29 (suppl_8): viii133-viii148. 10.1093/annonc/mdy279

Authors

N. Yamamoto1, Y. Fujiwara1, S. Kondo1, S. Iwasa1, K. Yonemori1, A. Shimomura1, S. Kitano1, T. Shimizu1, T. Koyama1, T. Ebata1, N. Sato2, K. Nakai3, M. Inatani4, K. Tamura1

Author affiliations

  • 1 Department Of Experimental Therapeutics, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Clinical Study Management Dept., Chugai Pharmaceutical Co., Ltd., 103-8324 - Tokyo/JP
  • 3 Clinical Pharmacology Dept., Chugai Pharmaceutical Co., Ltd., 103-8324 - Tokyo/JP
  • 4 Clinical Science & Strategy Dept., Chugai Pharmaceutical Co., Ltd., 103-8324 - Tokyo/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1151

Background

Navoximod is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1) which catalyzes the oxidation of L-tryptophan (Trp) into kynurenine (Kyn). This study aimed to investigate maximum tolerated dose (MTD), safety, pharmacokinetics (PK) and pharmacodynamics of navoximod as monotherapy and in combination with atezolizumab, an anti-PD-L1 antibody, in Japanese patients (pts) with advanced solid tumors.

Methods

Phase 1, open-label, 3 + 3 dose-escalation study. Primary endpoints were safety, tolerability, and PK. Pts received navoximod (400, 600 or 1000 mg orally twice daily [BID], for 21 days/cycle) monotherapy (Stage 1) or navoximod (200, 400, 600 or 1000 mg orally BID, for 21 days/cycle) in combination with atezolizumab (1200 mg IV, every 21 days) (Stage 2).

Results

Twenty pts were enrolled in the 400 mg (n = 3), 600 mg (n = 4) and 1000 mg (n = 3) cohorts of Stage 1, and in the 200 mg (n = 3), 400 mg (n = 3), 600 mg (n = 3) and 1000 mg (n = 1) cohorts of Stage 2. Across all cohorts, no DLT was observed and MTD was not reached in either stages. In Stage 1, treatment related adverse events (TRAEs) of any grade occurring in ≥ 20% of pts were chromaturia (50%) and maculopapular rash (20%). Grade ≥ 3 TRAEs were reported in 2 pts (20%), including maculopapular rash and lipase increased. In Stage 2, TRAEs ≥ 20% were fatigue (20%), chromaturia (60%), decreased appetite (40%), hyponatremia (20%), AST increased (20%), ALT increased (20%) and lymphopenia (20%). Grade ≥ 3 TRAEs were reported in 3 pts (30%), including hyponatremia, AST increased, ALT increased, lymphopenia and neutropenia. Cmax and AUC of navoximod as monotherapy were dose-proportional from 400 to 1000 mg and PK profile was similar in combination with atezolizumab. Reduction of Kyn in plasma was observed in accordance with concentration of navoximod. Stable disease (SD) was observed in 5 pts including 2 pts with SD > 4months in Stage 1, and in 8 pts including 4 pts with SD > 4months in Stage 2, respectively.

Conclusions

Navoximod as monotherapy and in combination with atezolizumab was generally well-tolerated in Japanese pts with linear PK and evidence of systemic inhibition of IDO1.

Clinical trial identification

JapicCTI-163330.

Legal entity responsible for the study

Chugai Pharmaceutical Co., Ltd.

Funding

Chugai Pharmaceutical Co., Ltd.

Editorial Acknowledgement

Disclosure

N. Yamamoto: Advisory board: Eisai, Takeda, OncoTherapy Science, Otsuka, Boehringer Ingelheim; Corporate sponsored research: Quintiles, Astellas, Chugai, Esai, Taiho, BMS, Pfizer, Novartis, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO. Y. Fujiwara: Advisory board: Bristol-Myers Squibb; Corporate-sponsored Research: Chugai, Incyte Corporation, MSD, Bristol-Myers Squibb. S. Iwasa: Corporate sponsored research: Bristol-Myers Squibb, Chugai. S. Kitano: Advisory board: Bristol-Myers Squibb, MSD. T. Shimizu: Corporate sponsored research: Bristol-Myers Squibb. N. Sato, K. Nakai, M. Inatani: Employment: Chugai. K. Tamura: Advisory Board: MSD; Corporate sponsored research: Chugai, Bristol-Myers Squibb, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.